HEPALINK：2025FIRSTQUARTERLYREPORT.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO.,LTD.（深圳市海普瑞藥業集團股份有限公司）(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock code:9989)2025 FIRST QUARTERLY REPORTThe Company and all the members

3、 of the board of directors confirm that all the information contained in this information disclosure is true,accurate and complete and that there is no false and misleading statement or material omission in this information disclosure.This announcement is published in accordance with Part XIVA of th

4、e Securities and Futures Ordinance(Chapter 571 of the Laws of Hong Kong)and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.The following is the 2025 first quarterly report of Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.(the“Compa

5、ny”or“Hepalink”,together with its subsidiaries referred to as the“Group”,“we”or“our”)for the three months ended March 31,2025(the“Reporting Period”).Its financial report was prepared in accordance with the PRC Accounting Standards and Accounting Regulations for Business Enterprises and was unaudited

6、.By order of the BoardShenzhen Hepalink Pharmaceutical Group Co.,Ltd.Li LiChairmanShenzhen,the PRCApril 24,2025 As at the date of this announcement,the executive directors of the Company are Mr.Li Li,Ms.Li Tan,Mr.Shan Yu and Mr.Zhang Ping;and the independent non-executive directors of the Company ar